Cargando…
Aspirin, a Potential GLUT1 Inhibitor in a Vascular Endothelial Cell Line
Recent epidemiological and preclinical studies have revealed that aspirin possesses antitumor properties; one of the mechanisms results from inhibition of angiogenesis. However, the underlying mechanisms of such action remain to be elucidated, in particular, the effect of aspirin on glucose metaboli...
Autores principales: | Hu, Yabo, Lou, Xiaohan, Wang, Ruirui, Sun, Chanjun, Liu, Xiaomeng, Liu, Shuochuan, Wang, Zibing, Ni, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744609/ https://www.ncbi.nlm.nih.gov/pubmed/31565672 http://dx.doi.org/10.1515/med-2019-0062 |
Ejemplares similares
-
IFNγ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins
por: Wang, Ruirui, et al.
Publicado: (2023) -
Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)
por: Khan, Hamzah, et al.
Publicado: (2021) -
HIV Protease Inhibitors Act as Competitive Inhibitors of the Cytoplasmic Glucose Binding Site of GLUTs with Differing Affinities for GLUT1 and GLUT4
por: Hresko, Richard C., et al.
Publicado: (2011) -
Cellular Metabolomics Reveal the Mechanism Underlying the Anti-Atherosclerotic Effects of Aspirin Eugenol Ester on Vascular Endothelial Dysfunction
por: Huang, Mei-Zhou, et al.
Publicado: (2019) -
Development of Glucose Transporter (GLUT) Inhibitors
por: Reckzeh, Elena S., et al.
Publicado: (2019)